Results 81 to 90 of about 7,464 (222)

Presentations Due to Priapism in an Urban Hospital in Switzerland

Emergency Medicine International, Volume 2026, Issue 1, 2026.
Objective Priapism, a persisting erection not associated with sexual stimulation, can be ischaemic, with the risk of permanent erectile dysfunction, or nonischaemic. Drugs—e.g., injection therapies for erectile dysfunction, as well as neuroleptics, antidepressants and various other medicines—can also cause priapism.
Julian Dionigi Uhl, Lukas Koneval, Laila Schneidewind, Manuel Haschke, Aristomenis Exadaktylos, Evangelia Liakoni, Shashank Kaushik   +6 more
wiley   +1 more source

Personalizing HIV therapy, mission impossible? [PDF]

, 2012
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source

Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study

Journal of the International AIDS Society, Volume 28, Issue 12, December 2025.
Abstract Introduction Cabotegravir + rilpivirine long‐acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV‐1 treatment in virologically suppressed (viral load [VL] <50 copies/mI individuals. In clinical trials, CAB+RPV LA was non‐inferior to oral antiretroviral therapy (ART) regimens in virologically suppressed individuals ...
Ricky K. Hsu, Michael G. Sension, Jennifer S. Fusco, Laurence Brunet, Quateka Cochran, Brooke Levis, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Michael B. Wohlfeiler, Gregory P. Fusco   +10 more
wiley   +1 more source

Mapping networks of anti-HIV drug cocktails vs. AIDS epidemiology in the US counties [PDF]

, 2014
[Abstract] The implementation of the highly active antiretroviral therapy (HAART) and the combination of anti-HIV drugs have resulted in longer survival and a better quality of life for the people infected with the virus.
González-Díaz, Humberto, Herrera-Ibatá, Diana María, Orbegozo-Medina, Ricardo Alfredo, Pazos, A.   +3 more
core   +2 more sources

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy

Advanced Science, Volume 12, Issue 44, November 27, 2025.
A vitiligo‐derived gene signature predicts response to immune checkpoint blockade across multiple cancer cohorts, providing a framework for patient stratification. Building on this, Fulvestrant—a clinically approved estrogen receptor degrader—further enhances antitumor immunity by reprogramming tumor‐associated macrophages and promoting CD8⁺ T cell ...
Jie Zhu, Liting Huang, Suzhen Bi, WeiKaixin Kong, Wanting Feng, Yingjia Li, Zhengwei Xie, Peipei Shan, Sujie Zhu   +8 more
wiley   +1 more source

A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction

BMC Infectious Diseases, 2018
Background Tenofovir alafenamide (TAF) is associated with less renal and bone toxicity compared with tenofovir disoproxil (TDF). TAF's recent FDA approval has spurred HIV providers to consider switching antiretroviral therapy (ART) regimens containing ...
Sarah S. Lee, Joshua P. Havens, Harlan R. Sayles, Jennifer L. O’Neill, Anthony T. Podany, Susan Swindells, Kimberly K. Scarsi, Sara H. Bares   +7 more
doaj   +1 more source

Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone

Case Reports in Infectious Diseases, 2019
Background. Single-tablet antiretroviral therapy is currently the first-line choice for the treatment of HIV infection. Some therapeutic regimens contain the CYP3A4 inhibitor cobicistat, which can interact with drugs undergoing hepatic first-pass ...
Roberto Pineda-Reyes, Alena Klochko
doaj   +1 more source

Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae [PDF]

, 2017
Mass administration of endectocides, drugs that kill blood-feeding arthropods, has been proposed as a complementary strategy to reduce malaria transmission.
Abizanda, Gloria, Aldaz, Azucena, Alustiza, Marta, Bilbao, José Ignacio, Castejon, Sandra, Chaccour, Carlos, Hammann, Felix, Irigoyen Barrio, Ángel, Maia, Marta F., Martí Soler, Helena, Moncada, Rafael, Pozo, José Luis Del, Tarimo, Brian B.   +12 more
core   +1 more source

Iatrogenic Cushing’s Syndrome Following Intra-Articular Triamcinolone Injection in an HIV-Infected Patient on Cobicistat Presenting as a Pulmonary Embolism: Case Report and Literature Review

International Medical Case Reports Journal, 2020
Marjan Alidoost, Gabriella A Conte, Khushboo Agarwal, Michael P Carson, Danielle Lann, Diane Marchesani Department of Medicine, Hackensack Meridian Health Jersey Shore University Medical Center, Neptune, NJ 07753, USACorrespondence: Marjan Alidoost Email
Alidoost M, Conte GA, Agarwal K, Carson MP, Lann D, Marchesani D   +5 more
doaj